脐带间充质干细胞联合环孢素治疗再生障碍性贫血5例并文献复习

doi:10.3969/j.issn.1671-7171.2017.02.003

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To observe the efficacy and safety of therapy with umbilical cord mesenchymal stem cells (MSC) combined with cyclosporine A (CSA) in aplastic anemia (AA). 【Methods】Five patients with aplastic anemia from January 2011 to December 2015 were collected and reviewed, which included four severe (SAA) cases and one non-severe (NSAA) case. All patients were treated with mesenchymal stem cells (intravenous infusion) and cyclosporine (intraosseous injection). The third to fifth generation of MSC cells were administered intravenously (1×10⁶/kg) to patients once a week for four consecutive weeks. Blood routine and bone narrow smears before and after treatment were checked. Adverse reactions after treatment were recorded. Reports on aplastic anemia published recently were searched for and summarized. 【Results】During an average follow-up period of 28 months ( 6 to 64 months) after MSC plus CSA therapy, two out of five cases were recovered, one was relieved, one was improved, and one was invalid, which was the NSAA case. 【Conclusion】To some extent, the therapeutic method of umbilical cord mesenchymal stem cells combined with cyclosporine for aplastic anemia was effective. There were no significant adverse reactions.

Key words： Umbilical Cord Mesenchymal Stem Cells Cyclosporine/TU Anemia, Aplastic/TH

Received: 02 February 2016

PACS:

R556.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2017.02.003 OR http://www.jcr.net.cn/EN/Y2017/V34/I2/215

[1] 庞希宁, 付小兵.干细胞与再生医学[M].北京,人民卫生出版社,2014:51-56.
[2] 张之南,沈悌.血液病诊断及疗效标准[M].3版,北京:科学出版社,2011:21.
[3] 齐薇薇,邵宗鸿,免疫性骨髓衰竭症[J].中华血液学杂志,2015,93(15):1189-1191.
[4] Zeng Y, Katsanis E.The complex pathophysiology of acquired aplastic anaemia[J].Clin Exp Immunol. 2015 ,180(3):361-370.
[5] 刘海芸,刘婷婷.再生障碍性贫血发病机制研究进展[J].中国实验血液学杂志, 2015, 23( 4) : 1216 -1220.
[6] Michelozzi IM, Pievani A, Pagni F et al.Human aplastic anaemia-derived mesenchymal stromal cells form functional haematopoietic stem cell niche in vivo[J].Br J Haematol,2016.
[7] Jiang S, Xie X, Jiang H, et al. Low expression of basic fibroblastic growth factor in mesenchymal stem cells and bone marrow of children with aplastic anemia[J].Pediatr Hematol Oncol,2014, 31(1): 11-19.
[8] Bacigalupo A, Valle M, Podestà M, et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia[J]. Experimental hematology, 2005, 33(7): 819-827.
[9] Hamzic E, Whiting K, Gordon Smith E, et al.Characterization of bone marrow mesenchymal stromal cells in aplastic anaemia[J].Br J Haematol,2015,169(6):804-813.
[10] Kastrinaki MC, Pavlaki K, Batsali AK, et al. Mesenchymal stem cells in immune-mediated bone marrow failure syndromes[J]. Clin Dev Immunol,2013, 2013:265608.
[11] 詹昱,陈玲珍,余卫,等.脐带间充质干细胞治疗再生障碍性贫血18例临床研究[J].国际医药卫生导报,2014,20(2):148-153.
[12] Xiao Y, Jiang ZJ, Pang Y, et al. Efficacy and safety of mesenchymal stromal cell treatment from related donors for patients with refractory aplastic anemia[J]. Cytotherapy, 2013, 15(7): 760-766.
[13] Clé DV, Santana-Lemos B, Tellechea MF, et al. Intravenous infusion of allogeneic mesenchymal stromal cells in refractory or relapsed aplastic anemia[J]. Cytotherapy, 2015, 17(12): 1696-1705.
[14] 蔡耘,陈惠芹,黄科.骨髓腔内输注脐带血及间充质干细胞对大鼠免疫重建影响[J].生物医学工程与临床,2010,14(5):369-373.
[15] Zhao K, Liu Q.The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation[J].J Hematol Oncol,2016,9(1): 46.